Qualigen Therapeutics, Inc. (7R9.F)

0.1820 +0.0780 (+75.00%) At close: 11:40AM CEST

Qualigen Therapeutics, Inc.

5857 Owens Avenue
Suite 300
Carlsbad, CA 92008
United States
760 452 8111
https://www.qlgntx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael S. Poirier	President, COO, CEO & Chairman	590.99k	N/A	1956
Mr. Christopher L. Lotz	VP of Finance, CFO & Corporate Secretary	540.41k	N/A	1965

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Corporate governance

Qualigen Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.